Vertex is continuing to ride high thanks to its near-monopoly in cystic fibrosis disease-modifying treatment, led by blockbuster Trikafta (elexacaftor/tezacaftor/ivacaftor).
The oral therapy earned $2bn and contributed to overall revenue growth of 13% in Q1, reflecting the expansion of its...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
